Esophageal Cancer Epigenomics and Integrome Analysis of Genome-Wide Methylation and Expression in High Risk Northeast Indian Population

OMICS A Journal of Integrative Biology

Volumn 19, Issue 11, 2015, Pages 688-699

  Singh, Virendra ^a   Singh, Laishram Chandreshwor ^a   Vasudevan, Madavan ^b   Chattopadhyay, Indranil ^c   Borthakar, Bibhuti Bhusan ^d   Rai, Avdhesh Kumar ^d   Phukan, Rup Kumar ^e   Sharma, Jagannath ^d   Mahanta, Jagadish ^e   Kataki, Amal Chandra ^d   Kapur, Sujala ^a   Saxena, Sunita ^a  

^a SAFDARJUNG HOSPITAL   (India)

^b Bionivid Technology Private Limited   (India)

^c CENTRAL UNIVERSITY OF TAMIL NADU   (India)

^d Dr B Borooah Cancer Institute ^*  (India)

^e Regional Medical Research Centre   (India)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; BIOLOGICAL MARKER; IL22RA2 PROTEIN; INTEGRIN; ONCOPROTEIN; SERPINA4 PROTEIN; TAC3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BMP8A GENE; CCDC80 GENE; CELL ADHESION; COL1A1 GENE; CONTROLLED STUDY; CTNNB1 GENE; CYTOSKELETON; DLX6 GENE; DNA METHYLATION; EPIGENETICS; ESOPHAGUS CANCER; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENOME ANALYSIS; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IL22RA2 GENE; INDIAN; METASTASIS; MICROARRAY ANALYSIS; NPC1 GENE; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PTK2 GENE; PZP GENE; RND1 GENE; RND3 GENE; SERPINA4 GENE; SIGNAL TRANSDUCTION; TAC3 GENE; TNFSF13B GENE; TUMOR GROWTH; UBL3 GENE; UGT2B4 GENE; UPREGULATION; BIOLOGY; CANCER GRADING; CLUSTER ANALYSIS; CPG ISLAND; ESOPHAGUS TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC EPIGENESIS; GENETICS; GENOME-WIDE ASSOCIATION STUDY; INDIA; MALE; METABOLISM; PATHOLOGY; PROCEDURES; PROTEIN ANALYSIS;

CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INDIA; MALE; NEOPLASM GRADING; PROTEIN INTERACTION MAPPING;

EID: 84947052951     PISSN: 15362310     EISSN: 15578100     Source Type: Journal    
DOI: 10.1089/omi.2015.0121     Document Type: Article

References (52)

1. Ahn JM, Sung HJ, Yoon YH, et al. (2014). Integrated glycoproteomics demonstrates fucosylated serum paraoxonase 1 alterations in small cell lung cancer. Mol Cell Proteomics 13, 30-48.
2. Baker M. (2013). Big biology: The 'omes puzzle. Nature 494, 416-419.
3. Bibikova M, Barnes B, Tsan C, et al. (2011). High density DNA methylation array with single CpG site resolution. Genomics 98, 288-295.
4. Chattopadhyay I, Singh A, Phukan R, et al. (2010). Genome-wide analysis of chromosomal alterations in patients with esophageal squamous cell carcinoma exposed to tobacco and betel quid from high-risk area in India. Mutat Res 696, 130-138.
5. Chattopadhyay I, Kapur S, Purkayastha J, et al. (2007). Gene expression profile of esophageal cancer in North East India by cDNA microarray analysis. World J Gastroenterol 13, 1438-1444.
6. Chattopadhyay I, Phukan R, Singh A, et al. (2009). Molecular profiling to identify molecular mechanism in esophageal cancer with familial clustering. Oncol Rep 21, 1135-1146.
7. Chiang JH, Cheng WS, Hood L, and Tian Q. (2014). An epigenetic biomarker panel for glioblastoma multiforme personalized medicine through DNA methylation analysis of human embryonic stem cell-like signature. OMICS 18, 310-323.
8. Chong Y, Mia-Jan K, Ryu H, et al. (2014). DNA methylation status of a distinctively different subset of genes is associated with each histologic Lauren classification subtype in early gastric carcinogenesis. Oncol Rep 31, 2535-2544.
9. Das M, Saikia BJ, Sharma SK, Sekhon GS, Mahanta J, and Phukan RK. (2015). p16 hypermethylation: A biomarker for increased esophageal cancer susceptibility in high incidence region of North East India. Tumour Biol 36, 1627-1642.
10. Das M, Sharma SK, Sekhon GS, Saikia BJ, Mahanta J, and Phukan RK. (2014). Promoter methylation of MGMT gene in serum of patients with esophageal squamous cell carcinoma in North East India. Asian Pac J Cancer Prev 15, 9955-9960.
11. Di Carlo E, D'Antuono T, Pompa P, et al. (2009). The lack of epithelial interleukin-7 and BAFF/BLyS gene expression in prostate cancer as a possible mechanism of tumor escape from immunosurveillance. Clin Cancer Res 15, 2979-2987.
12. Dimitrakopoulou K, Dimitrakopoulos GN, Sgarbas KN, and Bezerianos A. (2014). Tamoxifen integromics and personalized medicine: Dynamic modular transformations underpinning response to tamoxifen in breast cancer treatment. OMICS 18, 15-33.
13. Dumoutier L, Lejeune D, Colau D, and Renauld JC. (2001). Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22. J Immunol 166, 7090-7095.
14. Fang MZ, Jin Z, Wang Y, et al. (2005). Promoter hypermethylation and inactivation of O(6)-methylguanine-DNA methyltransferase in esophageal squamous cell carcinomas and its reactivation in cell lines. Int J Oncol 26, 615-622.
15. Fridley BL, Abo R, Tan XL, et al. (2014). Integrative gene set analysis: Application to platinum pharmacogenomics. OMICS 18, 34-41.
16. Herman JG, and Baylin SB. (2003). Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349, 2042-2054.
17. Huang KF, Huang XP, Xiao GQ, Yang HY, Lin JS, and Diao Y. (2014). Kallistatin, a novel anti-angiogenesis agent, inhibits angiogenesis via inhibition of the NF-κB signaling pathway. Biomed Pharmacother 68, 455-461.
18. Huber O, Bertrand C, Bunnett NW, et al. (1993). Tachykinins contract the circular muscle of the human esophageal body in vitro via NK2 receptors. Gastroenterology 105, 981-987.
19. Huber S, Gagliani N, Zenewicz LA, et al. (2012). IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 491, 259-263.
20. Ibanez de Caceres I, Dulaimi E, Hoffman AM, Al-Saleem T, Uzzo RG, and Cairns P. (2006). Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res 66, 5021-5028.
21. Jablonska E, Slodczyk B, Wawrusiewicz-Kurylonek N, et al. (2011). Overexpression of B cell-activating factor (BAFF) in neutrophils of oral cavity cancer patients - Preliminary study. Neoplasma 58, 211-216.
22. Jabłońska E, Wawrusiewicz-Kurylonek N, Garley M, et al. (2012). A proliferation-inducing ligand (APRIL) in neutrophils of patients with oral cavity squamous cell carcinoma. Eur Cytokine Netw 23, 93-100.
23. Jiang X, Li H, Qiao H, Jiang H, Xu R, and Sun X. (2009). Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. Cancer Sci 100, 2226-2233.
24. Jin Z, Olaru A, Yang J, et al. (2007) Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer. Clin Cancer Res 13, 6293-6300.
25. Kalled SL, Ambrose C, and Hsu YM. (2005). The biochemistry and biology of BAFF, APRIL and their receptors. Curr Dir Autoimmun 8, 206-242.
26. Karlsson A, Jönsson M, Lauss M, et al. (2014). Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome. Clin Cancer Res 20, 6127-6140.
27. Koppert LB, Wijnhoven BP, van Dekken H, Tilanus HW, and Dinjens WN. (2005). The molecular biology of esophageal adenocarcinoma. J Surg Oncol 92, 169-190.
28. Krysiak PS, and Preiksaitis HG. (2001). Tachykinins contribute to nerve-mediated contractions in the human esophagus. Gastroenterology 120, 39-48.
29. Li JS, Ying JM, Wang XW, Wang ZH, Tao Q, and Li LL. (2013). Promoter methylation of tumor suppressor genes in esophageal squamous cell carcinoma. Chin J Cancer 32, 3-11.
30. Li X, Zhou F, Jiang C, et al. (2014). Identification of a DNA methylome profile of esophageal squamous cell carcinoma and potential plasma epigenetic biomarkers for early diagnosis. PLoS One 9, e103162.
31. Lima SC, Hernández-Vargas H, Simão T, et al. (2011). Identification of a DNA methylome signature of esophageal squamous cell carcinoma and potential epigenetic biomarkers. Epigenetics 6, 1217-1227.
32. Lindqvist BM, Wingren S, Motlagh PB, and Nilsson TK. (2014). Whole genome DNA methylation signature of HER2-positive breast cancer. Epigenetics 9, 1149-1162.
33. Milutin Gašperov N, Farkas SA, Nilsson TK, and Grce M. (2014). Epigenetic activation of immune genes in cervical cancer. Immunol Lett 162, 256-257.
34. O'Connell J, O'Sullivan GC, Collins JK, and Shanahan F. (1996). The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184, 1075-1082.
35. Ohashi H, and Miyamoto-Sato E. (2014). Towards personalized medicine mediated by in vitro virus-based interactome approaches. Int J Mol Sci 15, 6717-6724.
36. Pennefather JN, Lecci A, Candenas ML, Patak E, Pinto FM, and Maggi CA. (2004). Tachykinins and tachykinin receptors: A growing family. Life Sci 74, 1445-1463.
37. Phukan RK, Ali MS, Chetia CK, and Mahanta J. (2001). Betel nut and tobacco chewing; potential risk factors of cancer of oesophagus in Assam, India. Br J Cancer 85, 661-667.
38. Podder A, and Latha N. (2014). New insights into schizophrenia disease genes interactome in the human brain: Emerging targets and therapeutic implications in the postgenomics era. OMICS 18, 754-766.
39. Schulmann K, Sterian A, Berki A, et al. (2005). Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 24, 4138-4148.
40. Sharma P, and Sharma R. (2015). miRNA-mRNA crosstalk in esophageal cancer: From diagnosis to therapy. Crit Rev Oncol Hematol. pii: S1040-8428(15)30002-0. doi: 10.1016/j.critrevonc.2015.07.002.
41. Shiau AL, Teo ML, Chen SY, et al. (2010). Inhibition of experimental lung metastasis by systemic lentiviral delivery of kallistatin. BMC Cancer 10, 245.
42. Sonnenberg GF, Fouser LA, and Artis D. (2010). Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces. Adv Immunol 107, 1-29.
43. Strand S, Hofmann WJ, Hug H, et al. (1996). Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion? Nat Med 2, 1361-1336.
44. Tecchio C, Scapini P, Pizzolo G, and Cassatella MA (2013). On the cytokines produced by human neutrophils in tumors. Semin Cancer Biol 23, 159-170.
45. Tse LY, Sun X, Jiang H, et al. (2008). Adeno-associated virus-mediated expression of kallistatin suppresses local and remote hepatocellular carcinomas. J Gene Med 10, 508-517.
46. Vidal M, Cusick ME, and Barabási AL. (2011). Interactome networks and human disease. Cell 144, 986-998.
47. Walch AK, Zitzelsberger HF, Bruch J, et al. (2000). Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. Am J Pathol 156, 555-566.
48. Warden CD, Lee H, Tompkins JD, et al. (2013). COHCAP: An integrative genomic pipeline for single-nucleotide resolution DNA methylation analysis. Nucleic Acids Res 41, e117.
49. Wong FH, Huang CY, Su LJ, et al. (2009). Combination of microarray profiling and protein-protein interaction databases delineates the minimal discriminators as a metastasis network for esophageal squamous cell carcinoma. Int J Oncol 34, 117-128.
50. Zhang J, Yang Z, Li P, Bledsoe G, Chao L, and Chao J. (2013). Kallistatin antagonizes Wnt/β-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6. Mol Cell Biochem 379, 295-301.
51. Zhi X, Lin L, Yang S, et al. (2015). βII-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin. Hepatology 61, 598-612.
52. Zhu B, Lu L, Cai W, et al. (2007). Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis. Mol Cancer Ther 6, 3297-3306.